Pediatric acute lymphoblastic leukemia. (2020)

• Record Type: Book
• Further Information: Note: Motohiro Kato, editor.
• Other Names: Katō, Motohiro
• Contents: Intro; Preface; Contents; Part I: Epidemiology and Diagnosis of Pediatric ALL; Chapter 1: Overview; 1.1 Introduction; 1.2 Symptoms and Diagnosis; 1.3 Treatment; 1.4 Future Directions; References; Chapter 2: Genetic Alterations of Pediatric Acute Lymphoblastic Leukemia; 2.1 B Precursor ALL with Recurrent Fusion or Chromosomal Abnormality; 2.1.1 KMT2A Rearrangement; 2.1.2 ETV6-RUNX1 and High Hyperdiploid; 2.1.3 TCF3 Rearrangement; 2.1.4 Hypodiploid; 2.1.5 BCR-ABL1; 2.2 New Subtype of B-ALL; 2.2.1 IKZF1 Deletion, CRLF2 Deregulation, and Ph-Like ALL; 2.2.2 iAMP21 2.2.3 MEF2D and ZNF384 Rearranged ALL2.2.4 DUX4 Rearranged ALL; 2.2.5 Others; 2.3 Genetic Alterations of T-ALL; 2.4 Genetic Alterations of Acute Leukemia Ambiguous Lineage; 2.5 Genetic Alterations of Relapsed B-ALL; 2.6 Clinical Implications of Genetic Studies; References; Chapter 3: Germline Biology of Pediatric ALL; 3.1 Importance of Germline Variants in Leukemia Biology; 3.2 Germline Biology for Drug Response; 3.2.1 Pharmacogenomics of Adverse Events; 3.3 Germline Biology for Leukemogenesis; 3.3.1 Leukemia Predisposing Syndrome; 3.3.2 Leukemia Predisposing in Non-syndromic ALL; References Chapter 4: Immunophenotype of Pediatric ALL4.1 Diagnostic Criteria of Pediatric ALL According to Immunophenotyping; 4.2 Immunophenotyping of B-Lineage ALL; 4.3 Immunophenotyping of T-Lineage ALL; 4.4 Relationship Between Immunophenotyping and Cytogenetic Abnormalities; References; Chapter 5: MRD in Pediatric ALL; 5.1 Introduction; 5.2 Detection Methods of Minimal Residual Disease; 5.2.1 PCR-Based MRD Detection; 5.2.2 FCM-Based MRD Detection; 5.3 Clinical Impact of MRD; 5.4 Future of Minimal Residual Disease Detection; References; Part II: Treatment of Pediatric ALL Chapter 6: B-Cell Precursor ALL6.1 Risk Stratification of B-Cell Precursor ALL; 6.2 Treatment Backbone of B-Cell Precursor ALL; 6.2.1 Induction Therapy; 6.2.2 Consolidation Therapy; 6.2.3 Maintenance Therapy; 6.2.4 CNS Directed Therapy; 6.2.5 Immunotherapy; References; Chapter 7: Pediatric T-Cell Acute Lymphobastic Leukemia; 7.1 Epidemiology; 7.2 Diagnosis; 7.3 Clinical and Biological Characteristics; 7.4 Treatment; 7.5 Prognostic Factors; 7.6 Future Directions; 7.7 Conclusion; References; Chapter 8: Mature B-Cell Acute Lymphoblastic Leukemia; 8.1 Epidemiology; 8.2 Pathology/Biology 8.3 Clinical Presentation8.4 Treatment; 8.4.1 Standard Treatments; 8.4.2 Relapsed or Refractory Disease; References; Chapter 9: Infant ALL; 9.1 Introduction; 9.2 Risk Stratifications in Infant ALL; 9.3 Treatment of Infant MLL-r ALL; 9.3.1 Chemotherapy; 9.3.2 Hematopoietic Stem Cell Transplantation; 9.3.3 Novel Therapies; 9.3.3.1 Nucleoside Analogues; 9.3.3.2 FLT3 Inhibitors; 9.3.3.3 Epigenetic Agents; 9.3.3.4 BCL-2 Inhibitors; 9.3.3.5 Immunotherapies; 9.4 Treatment of Infant MLL-g ALL; 9.5 Treatment of Relapsed Infant ALL; 9.6 Acute and Late Toxicities on Infant ALL Treatment; References
• Publisher Details: Singapore : Springer
• Publication Date: 2020
• Extent: 1 online resource (168 pages)
• Subjects: 618.92/99419; Lymphoblastic leukemia in children; Electronic books; Electronic books
• Languages: English
• ISBNs: 9789811505485; 9811505489
• Related ISBNs: 9789811505478; 9811505470
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.